Clinical Efficacy and Safety of Albendazole and Other Benzimidazole Anthelmintics for Rat Lungworm Disease (Neuroangiostrongyliasis): A Systematic Analysis of Clinical Reports and Animal Studies

Abstract The safety and efficacy of benzimidazole anthelmintics for the management of rat lungworm disease (neuroangiostrongyliasis) have been questioned regardless of the numerous global experimental animal studies and clinical reports. In this review, 40 of these experimental animal studies and 104 clinical reports are compiled with a focus on albendazole. Among the 144 articles involving an estimated 1034 patients and 2,561 animals, 4.1% were inconclusive or vague regarding the use of benzimidazoles. Of the remaining 138 articles, 90.5% found benzimidazoles to be safe and effective (885 patients; 2,530 animals), 4.3% as safe but ineffective (73 patients; 3 animals), and 5.0% caused adverse reactions (7 patients; 28 animals). Among the clinical reports with a confirmed diagnosis of neuroangiostrongyliasis in which albendazole monotherapy was used, 100% reported high efficacy (743 patients; 479 animals), and in those where albendazole-corticosteroid co-therapy was used, 97.87% were reported to be effective (323 patients; 130 animals).

Download Full-text

ОЦЕНКА ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ 10% ВНУТРИВЕННОГО ИММУНОГЛОБУЛИНА ПРИВИДЖЕН В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/raj.2020.16.4.006 ◽

2019 ◽

Author(s):

L.G. Khludova ◽

I.A. Manto ◽

E.A. Latysheva ◽

T.V. Latysheva ◽

M.R. Khaitov

Keyword(s):

Replacement Therapy ◽

Primary Immunodeficiency ◽

Adverse Reactions ◽

Efficacy And Safety ◽

High Efficacy ◽

Antibody Synthesis ◽

Human Immunoglobulins ◽

Severe Adverse Reactions ◽

Common Variable ◽

Real Clinical Practice

Актуальность. Заместительная терапия иммуноглобулинами человека является ведущим патогенетическим методом лечения первичных иммунодефицитов с нарушением синтеза антител. В настоящее время в России доступно несколько препаратов иммуноглобулинов человека нормальных для внутривенного введения. Цель. Оценить эффективность и безопасность препарата Привиджен (10 раствор иммуноглобулина для внутривенного введения) в реальной клинической практике в течение 12 клинических месяцев. Материалы и методы. 20 взрослых с диагнозом общая вариабельная иммунная недостаточности и Х-сцепленная агаммаглобулинемия получали внутривенный иммуноглобулин Привиджен к интервалом 243 дня в течение 12 мес. Первичными критериями оценки была частота инфекционных осложнений и нежелательных явлений. Результаты. У большинства пациентов в ходе исследования достигнут удовлетворительный претранс-фузионный уровень IgG. Тяжелых нежелательных явлений, связанных с введением препарата, не зарегистрировано. Заключение. В ходе исследования препарат продемонстрировал высокую эффективность и безопасность у пациентов, нуждающихся в ежемесячной заместительной терапииRelevance. Replacement therapy with human immunoglobulins is the leading pathogenetic method of treatment of primary immunodeficiency with impaired antibody synthesis. Currently, several preparations of human immunoglobulins for intravenous administration are available in Russia. Purposes. Evaluation of the efficacy and safety of Privigen immunoglobulin intravenous 10 liquid in real clinical practice within 12 clinical months. Methods. Twenty adults diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen infusions (0.2-0.4 mg/kg) at 243 intervals over a 12-month period. The primary endpoint was the annual rate of infections and adverse events. Results. Sufficient level of IgG was achieved in most patients during the study. Severe adverse reactions during the treatment were not registered. Conclusions. High efficacy and safety of monthly replacement therapy in patients with primary immunodeficiency with impaired antibody synthesis has been demonstrated.

Download Full-text

Meta-Analysis of Clinical Efficacy and Safety of Ligustrazine in the Treatment of Idiopathic Pulmonary Fibrosis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2020/2416132 ◽

2020 ◽

Vol 2020 ◽

pp. 1-11

Author(s):

Xiaozheng Wu ◽

Wen Li ◽

Zhenliang Luo ◽

Yunzhi Chen

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Clinical Symptoms ◽

Gas Analysis ◽

Control Group ◽

Efficacy And Safety ◽

Arterial Blood Gas ◽

Arterial Blood

Objective. To systematically review the efficacy and safety of Ligustrazine in the treatment of idiopathic pulmonary fibrosis (IPF). Methods. The electronic literature databases (PubMed, EMbase, CNKI, WanFang database, and VIP) were retrieved through a computer to find out the randomized controlled trials (RCT) of Ligustrazine in the treatment of IPF according to the inclusion/exclusion criteria screening test. Cochrane’s bias risk table was also used to evaluate the quality of the study and to extract effective data. RevMan 5.3 was used for statistical analysis. Results. A total of 7 RCTs (a total of 366 patients, including 196 in experimental and 170 in control group). Compared with the control group, Ligustrazine could improve the clinical symptoms ([OR] = 2.20, 95% CI [1.40, 3.46], P = 0.0006 ), lung function (VC % [MD] = 3.92, 95% CI [0.68, 7.17], P = 0.02 ), (TLC% [MD] = 4.94, 95% CI [0.37, 9.52], P = 0.03 ), the pulmonary diffusion function (DLCO % [MD] = 9.12, 95% CI [5.70, 12.55], P < 0.00001 ), and arterial blood gas analysis (PaO2 [MD] = 7.11, 95% CI [1.96, 12.25], P = 0.007 ) (PaCO2 [MD] = −2.42, 95% CI [−4.36, −0.49], P = 0.01 ) of IPF patients, respectively. However, FEV1/FVC % ([MD] = 9.37, 95% CI [−1.23, 19.97], P = 0.08 ) and adverse reactions ([MD] = 0.35, 95% CI [0.02, 5.36], P = 0.45 ) were not significantly improved. Conclusion. Ligustrazine has certain clinical efficacy in the treatment of IPF, but the safety of applying it and the adverse reactions need to be further analyzed and determined. It can be considered as a new alternative and complementary medicine to be promoted and recommended for use in medical units in various countries in the world and it solved the difficult problem of conventional drug treatment of IPF; therefore, more research strength can be put in the treatment of the pathological mechanism of IPF for further exploration. The study was registered under registration number CRD42020193626.

Download Full-text

Clinical Evaluation of Ramosetron Injections in the Treatment of Cisplatin-Induced Nausea and Vomiting

Journal of International Medical Research ◽

10.1177/147323000203000301 ◽

2002 ◽

Vol 30 (3) ◽

pp. 211-219 ◽

Cited By ~ 6

Author(s):

K Noda ◽

M Ikeda ◽

O Yoshida ◽

S Yano ◽

T Taguchi ◽

...

Keyword(s):

Cancer Patients ◽

Clinical Efficacy ◽

Clinical Evaluation ◽

Adverse Reactions ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Efficacy Analysis

A phase III, double-blind, placebo-controlled study was performed to examine the safety and efficacy of ramosetron in cancer patients with cisplatin-induced nausea/vomiting. Patients were divided into two groups: group R received 0.3 mg ramosetron intravenously and group P received placebo. Eighty-eight patients were enrolled, 44 in each group; 84 (43 in group R, 41 in group P) were included in the clinical efficacy analysis and 86 (44 in group R, 42 in group P) in the safety analysis. Ramosetron was significantly more clinically effective than placebo against nausea, vomiting and anorexia; 65.1% of patients in group R experienced no vomiting in the first 6 h of observation compared with 7.3% of those receiving placebo. No serious adverse reactions or significant differences in safety were observed between the groups. Based on these results, ramosetron injection is effective in the treatment of cisplatin-induced nausea/vomiting and its clinical usefulness is demonstrated here.

Download Full-text

The Relationship between Compound Danshen Dripping Pills with Isosorbide Mononitrate in the Treatment of Elderly Patients with Unstable Angina Pectoris

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2018/3429151 ◽

2018 ◽

Vol 2018 ◽

pp. 1-12 ◽

Cited By ~ 1

Author(s):

Yulin Liang ◽

Junbo Zou ◽

Xiaofei Zhang ◽

Yu Wang ◽

Jia Tai ◽

...

Keyword(s):

Angina Pectoris ◽

Unstable Angina ◽

Clinical Efficacy ◽

Blood Viscosity ◽

Whole Blood ◽

Adverse Reactions ◽

Meta Analysis ◽

The Elderly ◽

Isosorbide Mononitrate ◽

Efficacy And Safety

Objective. To evaluate the clinical efficacy and safety of Compound Danshen Dripping Pill (CDDP) and Isosorbide Mononitrate (ISMN) in the treatment of unstable angina pectoris (UAP) in the elderly. Materials and Methods. CNKI, Wanfang, VIP, CBM, and PubMed databases were searched for appropriate articles without language limitations on keywords. RevMan 5.3 software was used to perform the meta-analysis. Results. This analysis compared CDDP with ISMN of 21 randomized controlled trials (RCTs) that involved a total of 2356 patients with UAP. When the treatment lasted for four weeks, the clinical effective rate was OR = 3.97, 95% CI = 2.97, 5.30, and P < 0.00001, the ECG efficiency was OR = 3.43, 95% CI = 2.13, 5.53, and P < 0.00001, and incidence of adverse reactions was OR = 0.73, 95% CI = 0.52, 1.04, and P = 0.08 > 0.05. When the treatment lasted for eight weeks, clinical efficiency rate was OR = 4.22, 95% CI = 2.37, 3.79, and P < 0.00001, incidence of adverse reactions was OR = 0.58, 95% CI = 0.26, 1.27, and P = 0.17 > 0.05, whole blood low-cut blood viscosity was SMD = -0.61 and 95% CI -1.60, 0.38, whole blood high-cut blood viscosity was SMD = -0.38 and 95% CI -0.97, 0.21, and blood cells specific volume was SMD = -0.80 and 95% CI -2.61, 1.01. Conclusion. Based on this meta-analysis, the CDDP was superior to ISMN with UAP in the elderly. However, there is still a need to further verify the clinical efficacy and safety of CDDP with more strictly designed RCTs with large sample and multiple centers in the future.

Download Full-text

Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/6640594 ◽

2021 ◽

Vol 2021 ◽

pp. 1-27

Author(s):

Yan-Li Guo ◽

Feng Gao ◽

Tai-Wei Dong ◽

Yang Bai ◽

Qiao Liu ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Nephrotic Syndrome ◽

Kidney Disease ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Meta Analysis ◽

Computer Search ◽

Efficacy And Safety ◽

Tripterygium Wilfordii

Objective. Tripterygium wilfordii polyglycosides tablet (TGt) is an oral preparation extracted from plant Tripterygium wilfordii. It has the effects of anti-inflammation and inhibition of cellular and humoral immunity. However, many reports of adverse reactions caused by TGt have limited its application. In this paper, the clinical efficacy and safety of TGt in the treatment of chronic kidney disease (CKD) were verified by data mining and analysis, so as to provide theoretical data support for the application and development of TGt. Methods. A computer search of the following databases was conducted: PubMed, Web of Science, CBM, VIP, Wanfang Data, and CNKI. The search time limit is from the establishment of the database to September 2020. We searched for clinical randomized controlled trials of TGt in the treatment of CKD. The main types of CKD involved are nephrotic syndrome (NS), primary nephrotic syndrome (PNS), refractory nephrotic syndrome (RNS), and IgA nephropathy (IgAN). RevMan 5.2 and Stata 12.0 software were used to evaluate the literature quality and analyze the data. Finally, GRADEpro software was used to evaluate the quality of evidence. Results. According to the inclusion and exclusion criteria, 75 articles with a total of 6418 subjects were included. The results of the meta-analysis showed that TGt could reduce 24-hour urinary protein, increase serum albumin, improve clinical efficacy, and reduce disease recurrence rate in patients ( P < 0.05 ) with CKD compared with adrenocortical hormones or immunosuppressants. TGt could significantly reduce the level of serum creatinine (Scr) in patients with CKD ( P < 0.05 ), but it was not significant in reducing the level of blood urea nitrogen ( P > 0.05 ). In terms of safety evaluation, in patients with CKD, it could significantly reduce the incidence of gastrointestinal adverse reactions and neurogenic dizziness and headache ( P < 0.05 ). However, in terms of adverse reactions such as liver injury, respiratory infection, and leukopenia, TGt was as harmful as corticosteroids or immunosuppressants ( P < 0.05 ). The quality of the evidence was evaluated with GRADEpro software, and the results showed that TGt was strongly recommended for the treatment of CKD. Conclusion. TGt has certain efficacy in the treatment of CKD and has fewer side effects in certain types of diseases. The effect of TGt combined with other drugs is better than that of single use. This paper also has some limitations. Due to the limited number of the included studies, with all being from China, there may be methodological differences. Therefore, more high-quality literature data from different countries are needed.

Download Full-text

Clinical Efficacy & Safety of Oral Polypodium Leucotomos Extract for Photoprotection: A Systematic Review

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.6.2 ◽

2018 ◽

Cited By ~ 1

Author(s):

Giselle Prado ◽

Rebeca Teplitz ◽

Richard Winkelmann ◽

James Del Rosso ◽

Darrell Rigel

Keyword(s):

Systematic Review ◽

Adverse Effects ◽

Clinical Efficacy ◽

Risk Of Bias ◽

Data Collection Form ◽

Efficacy And Safety ◽

Safety And Efficacy ◽

Collection Form ◽

Polypodium Leucotomos ◽

Minimal Evidence

Background: Polypodium leucotomos extract (PLE) is a naturally derived compound from a fern native to South America. PLE has been shown to have antioxidant and photoprotective properties. Several different preparations of PLE are commercially available.Objective: To review the efficacy and safety of PLE for photoprotection in humans.Methods: A systematic review was conducted in 3 databases (Medline, Embase, and Cochrane) for studies that reported on the clinical efficacy and safety of PLE in humans. A data collection form was created for collecting study variables and risk of bias was assessed.Results: Eighteen studies with sample sizes ranging from n=5 to n-61 were included. The most common formulation of PLE studied was Fernblock® (Heliocare, Ferndale Healthcare, Ferndale, MI) in 18 studies. Most studies reported beneficial photoprotective effects of PLE as evidenced by increased MED. No serious adverse effects were reported.Conclusions: Multiple studies have shown the beneficial photoprotective effects and safety of the Fernblock® PLE formulation, but there is minimal evidence to support the safety and efficacy of other formulations. Given that the extraction methodology varies for herbal nutraceuticals and can affect its efficacy, these findings cannot be extrapolated to other formulations of PLE.

Download Full-text

Study on the Clinical Efficacy and Safety of Endostar Combined with Pemetrexed and Cisplatin in the Treatment of Lung Adenocarcinoma

Proceedings of Anticancer Research ◽

10.26689/par.v4i6.1676 ◽

2020 ◽

Vol 4 (6) ◽

Author(s):

Yanbing Wang

Keyword(s):

Lung Adenocarcinoma ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Treatment Plan ◽

Specific Treatment ◽

Control Group ◽

Efficacy And Safety ◽

Treatment Results ◽

Significant Difference ◽

Experimental Group

Objectives: To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma. Methods: From August 2016 to September 2020, 32 patients with lung adenocarcinoma who were treated in our hospital were selected for group trials. According to their specific treatment plan, the patients were divided into control group and experimental group, with 16 cases in each group. The control group was treated with pemetrexed and cisplatin, and the experimental group was treated with Endostar combined with the treatment received by the control group. The clinical efficacy and safety of the two regimens were assessed by comparing the changes in symptoms and the incidence of adverse reactions between the two groups of patients after treatment. Results: The disease control rate of the experimental group was significantly higher than that of the control group, and there was no significant difference in the incidence of adverse reactions between the two groups. Conclusions: From the experimental results, we found that the treatment of patients with lung adenocarcinoma by Endostar combined with pemetrexed and cisplatin can effectively improve the treatment efficacy without increasing adverse reactions and therefore relevant chemotherapy regimens can be considered for wider clinical applications.

Download Full-text

CLINICAL EFFICACY OF EBASTINE IN PATIENTS SUFFERING FROM SPONTANEOUS URTICARIA

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja402 ◽

2016 ◽

Vol 13 (4-5) ◽

pp. 82-87

Author(s):

O G Elisyutina ◽

E S Fedenko ◽

E N Zemskaya ◽

O V Shtyrbul

Keyword(s):

Clinical Efficacy ◽

Chronic Urticaria ◽

Activity Score ◽

Efficacy And Safety ◽

High Efficacy ◽

First Line ◽

Once Daily ◽

Acute Urticaria ◽

Urticaria Activity Score

Background. To evaluate the efficacy and safety of Kestine® (ebastine) 20 mg sublingual tablets in spontaneous urticaria. Materials and methods. 25 adults suffered from spontaneous chronic urticaria, and 5 patients with acute urticaria aged from 18 to 56 years old (mean age 32,7±10,1) were included in the study. All patients received treatment with Kestine® (ebastine) 20 mg 1 sublingual tab. once daily during 28 days. Assessment of activity and severity of urticaria symptoms was carried out before the treatment, 2 and 4 weeks after the starting of the treatment. To assess the urticaria activity symptoms the urticaria activity score uAS and uAS 7 (for 7 days) were used. Results. The study showed high efficacy and safety of ebastine 20 mg sublingual tablets in the treatment of patients with chronic and acute urticaria. Control under the symptoms was achieved in 20 patients with chronic urticaria (mediana UAS7 before treatment 27 - Q1 - 21, Q3 - 34, after the treatment - 10 - Q1 - 4, Q3 - 12) and in 5 patients with acute urticaria on the 28th day of treatment. Thus Kestine® (ebastine) 20 mg can be recommended as the first line medication in the treatment of spontaneous urticaria.

Download Full-text